Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Long-term Open-label Continuation Study of the Safety and Efficacy of Belimumab for Up to 7 Years in Patients with Systemic Lupus Erythematosus from Japan and South Korea. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Long-term Open-label Continuation Study of the Safety and Efficacy of Belimumab for Up to 7 Years in Patients with Systemic Lupus Erythematosus from Japan and South Korea. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.